icad inc. (NASDAQ:ICAD - Get Free Report)'s share price passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $2.78 and traded as high as $3.78. icad shares last traded at $3.75, with a volume of 166,301 shares.
Wall Street Analysts Forecast Growth
ICAD has been the topic of a number of recent analyst reports. Laidlaw reiterated a "hold" rating on shares of icad in a report on Thursday, April 17th. BTIG Research lowered icad from a "buy" rating to a "neutral" rating in a report on Wednesday, April 16th. Wall Street Zen initiated coverage on icad in a research note on Tuesday, May 20th. They issued a "sell" rating for the company. Finally, Craig Hallum cut icad from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, April 16th.
Get Our Latest Stock Analysis on ICAD
icad Stock Up 2.9%
The stock has a market capitalization of $106.03 million, a PE ratio of -20.32 and a beta of 1.38. The firm's fifty day moving average price is $3.66 and its two-hundred day moving average price is $2.78.
icad (NASDAQ:ICAD - Get Free Report) last announced its earnings results on Tuesday, May 13th. The technology company reported ($0.02) earnings per share for the quarter, beating analysts' consensus estimates of ($0.06) by $0.04. The business had revenue of $4.87 million during the quarter, compared to analyst estimates of $4.54 million. icad had a negative net margin of 26.63% and a negative return on equity of 15.03%.
Institutional Investors Weigh In On icad
Several hedge funds and other institutional investors have recently made changes to their positions in ICAD. Parkman Healthcare Partners LLC purchased a new position in shares of icad in the first quarter worth approximately $1,610,000. Informed Momentum Co LLC purchased a new position in shares of icad during the 1st quarter worth $593,000. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of icad during the 1st quarter worth $505,000. Jane Street Group LLC bought a new stake in shares of icad during the 1st quarter valued at $180,000. Finally, Granahan Investment Management LLC purchased a new stake in shares of icad in the 4th quarter worth $96,000. Hedge funds and other institutional investors own 24.61% of the company's stock.
About icad
(
Get Free Report)
iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.
Read More
Before you consider icad, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and icad wasn't on the list.
While icad currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
